Treadwell Therapeutics’ CFI-402257 Granted Fast-Track Status by FDA
China-based clinical-stage biotech Treadwell Therapeutics has announced receiving fast-track status from the US Food and...
Treadwell Therapeutics
Treadwell Therapeutics Presents PLK4 Inhibitor Data at ASH Annual Meeting
China-based Treadwell Therapeutics presented results of the company’s CFI-400945 program, a first-in-class inhibitor of Polo-like...